Skip to main content
HomeInvestors hub
alt text

PhotocureInvestor Hub

Investment highlights

A commercial-stage company focused on bladder cancer

Hexvix®/Cysview® is a product for the detection of bladder cancer:

  • Established position as an innovation leader in the large and underserved bladder cancer treatment market
  • Treatment guidelines and reimbursement supports market penetration
  • In excess of NOK 500 million in global revenue in 2024
  • Specialist salesforce established in North America and Europe with additional potential value in other territories through our partners; Asieris MediTech Co., Ltd. (China), Endotherapeutics Group (Australia/New Zealand), Genotests (Chile) and IGL Medical (Israel)

Read the corporate overview.

Value-building opportunity

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories
  • Potential for FDA to down-classify blue light cystoscopy and open the 510k pathway to enable more manufacturers to enter the U.S. market
  • Opportunity for Photocure to launch a proprietary flexible blue light cystoscope system to expand the surveillance market globally
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure

Investor news

OSE Notice
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results
Oslo, Norway
11 February 2026
PRESS-RELEASE
New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment
Oslo, Norway
12 January 2026
NEWS POST
New publication: examining 12-months recurrence-free survival following photo coagulation of bladder tumor versus TUR-BT
Oslo, Norway
8 January 2026
PRESS-RELEASE
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
Oslo, Norway
8 December 2025
NEWS POST
Photocure receives prestigious Innovation Prize from the Norwegian Cancer Society: Recognition for Groundbreaking Contributions in Bladder Cancer Diagnostics
Oslo, Norway
28 November 2025
PRESS-RELEASE
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
Oslo, Norway
19 November 2025
OSE Notice
Photocure ASA: Notification of primary insider transaction
Oslo, Norway
31 October 2025
OSE Notice
Photocure ASA: Results for the third quarter of 2025
Oslo, Norway
29 October 2025
OSE Notice
Photocure ASA: Invitation to presentation of third quarter 2025 financial results
Oslo, Norway
24 October 2025
PRESS-RELEASE
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
Oslo, Norway
15 October 2025
NEWS POST
Photocure Partner Asieris publishes Phase III Results from the APRICITY Study for Cevira (APL-1702) in Med journal
Oslo, Norway
10 October 2025
OSE Notice
Photocure ASA - Share option grant
Oslo, Norway
22 September 2025
NEWS POST
Photocure raises awareness at EU Roundtable and Report on bladder cancer
Oslo, Norway
16 September 2025
PRESS-RELEASE
Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review
Oslo, Norway
4 August 2025
OSE Notice
Photocure ASA: Results for the second quarter of 2025
Oslo, Norway
30 July 2025
PRESS-RELEASE
Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results
Oslo, Norway
22 July 2025

Latest reports

Event highlights

Congresses

Society of Urologic Oncology 2025 Annual Meeting (SUO)

2 Dec 2025 - 5 Dec 2024https://suonet.org/meetings/upcoming-meetings.aspx

Conferences

DNB/Back Bay 10th Annual Nordic-American Healthcare Conference

26 Mar 2026 - 27 Mar 2026

Conferences

25th Annual Needham Virtual Healthcare Conference

13 Apr 2026 - 16 Apr 2026

Analyst coverage Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management. Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

ABG Sundal Collier

Georg Tigalonov-Bjerke, MD
Tel: +47 22 01 60 84

DNB Bank ASA

Geir Hillier Holom
Tel: +47 977 66 583
 

Handelsbanken

Justė Subatavičiūtė
Tel: (+370) 605 82 527